Drugs / Nanobody-based biepitope BCMA-targeting CAR-T cell
Nanobody-based biepitope BCMA-targeting CAR-T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06503107 | Apr 2024 → Apr 2026 overdue | plasma cell myeloma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanobody-based biepitope BCMA-targeting CAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06503107 ↗ |
| Action | Deplete | “The structure of BCMA target CAR-T is designed to identify two different epitopes of BCMA protein with two recognition domains, in order to killig MM cells without secreting...” NCT06503107 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT06503107 ↗ |